Abstract: Irritable Bowel Syndrome (IBS) may be diagnosed on the presence of symptoms, according to Rome II criteria and some studies have shown that abnormal colonic fermentation may be an important factor in the development of symptoms in some patients with IBS. Since the fermentations of substrates by the intestinal flora may play a key role in the use of probiotics in the treatment of IBS, fifty patients (24 males,26 females), mean age 40 years (range = 26-64 years) with IBS, according to Rome II criteria, were enrolled into the study after informed consensus. Patients were randomly assigned to receive either the active preparation containing Lactobacillus Plantarum LP0 1 and Bifidocterium Breve BR0 both at a concentration of 5 × 10 9 CFU/ml, or placebo powder containing starch identical to the study product, for 4 weeks. To evaluate treatment efficacy two different scores were considered: Pain score in different abdominal locations after treatment decreased in probiotics group of 38% versus 18% (P < 0.05) of placebo group after 14 days and of 52% versus 11% (P < 0.001) after 28 days. The severity score of characteristic IBD symptoms significantly decreased in probiotic group versus placebo group after 14 days 49.6% versus 9.9% (P < 0.001) and these data were confirmed after 28 days (44.4% versus 8.5%, P < 0.001). In conclusion, short-term therapy with Lactobacillus PlantarumLP0 1 and Bifidocterium Breve BR0 may be considered a promising approach to the therapy for IBS.
S
ome studies have shown that abnormal colonic fermentation may be an important factor in the development of symptoms in some patients with IBS. 2 In man,the large gut receives material from the ileum which has already been digested and the contents are then mixed and retained for 6-12 hours in the cecum and right colon. 3 Thus, the large intestine is an open system, with nutrients flowing in the cecum, and bacteria, their metabolic products, and undigested foodstuffs being excreted as faeces. The anaerobic brakdown of carbohydrate and protein by bacteria is known conventionally as fermentation. In man the major end products are the schort chain fatty acids (SCFA) acetate, propionate, butirate, the gases H2 and CO2, ammonia, amines, phenols and energy, which the bacteria use for growth and the maintenance of cellular function.
Fermentation is active in right colon with high bacterial growth rates and a totalSCFA production of 127 mmol/l at pH = 5.4-5.9; in transverse colon there is a reduction in bacterial activity due to depletion of substrates and a total SCFA production = 117 mmol/l at pH = 6.2; in the left colon the carbohydrate fermentation is little, with a high fermentation of protein with production of phenols, indoles, ammonia. 4 The fermentations of substrates by the intestinal flora may play a key role in the use of probiotics in the treatment of IBS. Probiotics are live bacteria food supplements that benefit the host animal by improving the intestinal microbial balance. Recents studies emphasize the role of probiotics in regulating the motility of the digestive tract. 9 In an open study Lactobacillus plantarum DSM9843 has been received by patients suffering for IBS during 4 weeks with reduction of flatulence and abdominal pain.The probiotic has been recovered in faeces and rectal biopsies respectively in 84% and 34% of treated subjects. 5 To assess the efficacy of Lactobacillus plantarum 299V in IBS, 40 patients were randomized to receive either the probiotic in liquid suspension (20 patients) or placebo (20 patients) over a period of 4 weeks. Clinical examination was performed at baseline and at the end of the study. Additionally, patients assessed their symptoms by applying a scoring system. All patients treated with the probiotic reported resolution of their abdominal pain as compared with 11 patients from the placebo group. There was also a trend toward normalization of stools frequency in constipated patients in 6 out of 10 patients treated with probiotic versus 2 out of 11 in the placebo group. With regards to all IBS symptoms an improvement was noted in 95% of patients in probiotic group versus 15% in the placebo group. 6 VSL#3, a composite product containing multiple strains of 3 viable lyophilized bacteria species (Lactobacilli, Bifidobacteria, Streptococcus), has been tested in 42 patients with IBS with advantage on pain in 81% of cases and a decrease of stool frequency from 7.2 ± 2 to .1 ± 1.1 (P < 0.002) 7 ; in an other trial recently published VSL#3 appears to be promising in the relief of abdominal bloating in patients with diarrhea predominant IBS. 8 A recent editorial suggests the importance to plan randomized trials with an adeguate number of patients randomly allocated to probiotics or placebo to define the possibility to use probiotics in the treatment of IBS. 9 We undertook a placebo-controlled study to define the efficacy of a 2 composite product containing the first one strain of Lactobacillus plantarum LP01 plus one strain of Bifidocterium breve BR0, the second a strain of Lactobacillus plantarum LP01 plus a strain of Lactobacillus acidophilus LA02 versus placebo in the treatment of IBS.
PATIENTS, MATERIAL AND METHODS.
Seventy patients (31 males, 39 females), mean age 40 years (range = 26-64 years) with IBS were enrolled in to the study after informed consensus. All patients had a previous history of IBS according to Rome II criteria 1 and with an exclusion of organic diseas on the basis of abdominal ultrasound and colonoscopy, treated with different drugs, without success.
Patients were randomly assigned to receive twice a day for 4 weeks: 
RESULTS
Seventy patients have been considered valuable on the basis of "intention to treat": 24 in Group A, 26 in Group B, 20 in Placebo Group.
The ovarall "pain socre" (Table 1) in Group A decreased by 42% and 45%, respectively, at day 14 and at day 28; in Group B by 49% both at days 14 and 28; in placebo Group by 25% and 29.5%. The best results were achieved for pain in RLQ and LLQ.
The overall symptoms score (Table 2) in Group A decreased by 49.3% and 56%, respectively, at day 14 and at day 28; in Group B by 55.6%, both at days 14 and 28; in placebo Group by 8% and 14.4%.
No statistical evaluation is possible due to the small number of patients studied, but a clear advantage for probiotic treated group versus placebo is evident.
In conclusion the preparations containing Lactobacillus plantarum LP01 (Probial) + Bifidocterium breve BR0 (Probial) and Lactobacillus plantarum LP0 (Probial)1 + Lactobacillus acidophilus LA0 (Probial) 2, may both be considered an interestin tool in the terapy of IBS. Further studies are needed to confirm these preliminary data.
